Michael Hunt, chief financial officer at ReNeuron (LON:RENE), tells Proactive Investors about the US trial where the first human patient suffering from blindness-causing disease, retinitis pigmentosa, was treated using the company's cell therapy candidate.
He hopes ReNeuron's treatment will "at the very least" arrest the deterioration in eyesight caused by the disease and in the best case restore sight.
Hunt hopes to get first data for retinitis pigmentosa Phase I/II US trial before end 2016. Subject to the outcome of this study, he expects ReNeuron to be able to file an application in the second half of 2017 to commence a pivotal Phase II/III clinical trial with its cell therapy candidate.
He says the next significant milestone for the company if all goes well will be the data from its strokes study in a Phase II clinical trial in the UK.